MUMBAI, INDIA- November 17, 2000 - India's powerful combination of expanding medical and information technology expertise is driving the country's growth as a center for global pharmaceutical research and development, said Dennis Gillings, Ph.D., Chairman and Chief Executive Officer of Quintiles Transnational Corp., the world's leading contract healthcare organization.
At a press conference held today in Mumbai as part of ceremonies to dedicate Quintiles' newest office in India, Gillings spoke about India's potential as a center to develop new and better medicines and what Quintiles is doing to improve healthcare for India's 1 billion people.
"I believe India will play a pivotal role in global research and development for the pharmaceutical industry, providing opportunities for India's scientists, researchers and medical institutions to access the latest advances in medicine," Gillings said. "With information technology increasingly playing a crucial role in pharmaceutical R&D, India's universally acknowledged expertise in the IT sector will give it a leadership edge in driving clinical research for global and local pharmaceutical companies."
Quintiles opened its first office in India in 1997 and has since been building the infrastructure and knowledge base needed to support India's own emerging research-based pharmaceutical industry. In less than three years, Quintiles Spectral (India) Ltd. has grown to 60 employees in three locations - Ahmedabad, Bangalore and Mumbai.
As the country's leading pharmaceutical service provider, Quintiles conducts courses in Good Clinical Practices (GCP) to train physicians and helps finance needed research infrastructure and equipment for hospitals that serve as study sites. Quintiles now offers a full range of drug development services in India, including study protocol development, Phase II through IV drug trials, data management and biostatistical analysis.
In discussing how Quintiles' worldwide Internet strategy fits into its India operations, Gillings said: "We believe Internet-based research services will be a paradigm shift for the pharmaceutical industry, bringing tremendous benefits to develop drugs faster and more efficiently. Quintiles is developing Web-based tools for drug research and other services via the Internet. With the Indian government identifying pharmaceuticals and information technology as areas of focus for economic development, I believe Quintiles is positioned to synergize the two sectors."
Quintiles currently is conducting clinical research for pharmaceutical companies involving more than 70 research sites, said Ferzaan Engineer, Ph.D., Managing Director, Quintiles Spectral (India) Limited.
"Quintiles is building a knowledge base and infrastructure that are needed by India's own pharmaceutical companies with strong research pipelines," Engineer said. "We are involved in over 30 research projects for 20 different pharmaceutical companies, and more than 50 percent of our international clients are repeat customers."
Executive Director Narges Mahaluxmivala, who heads Quintiles Spectral's clinical operations, said: "Clinical research benefits India in so many ways. It provides access to the latest advances in medicine. It gives India's physicians the opportunity to participate in global research programs and to publish internationally. The ability to conduct quality research requires the highest level of expertise, and clinical trials are a mechanism for knowledge transfer.
"We have upgraded facilities at over 70 hospitals and provided GCP training for more than 100 investigators over the past three years. Training investigators and sharing best research practices enhance the overall quality of healthcare services in India."
The Indian government recently approved Quintiles as a commercial R&D company, an important designation that recognizes Quintiles' contributions to the drug research industry and Quintiles' status among pharmaceutical service organizations in India.
Quintiles Transnational is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles employs a global workforce of more than 19,000 in 38 countries. Quintiles Transnational is a member of the S&P 500, Fortune 1000 and Nasdaq 100. For more information visit the company's Web site at www.quintiles.com.
Information in this press release contains "forward-looking statements" about Quintiles. These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the ability to development new products and services, the development of the Indian market, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, the ability to create data products from data licensed to us and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.